@article{f09413d7a2a449bdad0b35e7a280a764,
title = "Serial correlation structures in latent linear mixed models for analysis of multivariate longitudinal ordinal responses",
abstract = "We propose a latent linear mixed model to analyze multivariate longitudinal data of multiple ordinal variables, which are manifestations of fewer continuous latent variables. We focus on the latent level where the effects of observed covariates on the latent variables are of interest. We incorporate serial correlation into the variance component rather than assuming independent residuals. We show that misleading inference may be drawn when misspecifying the variance component. Furthermore, we provide a graphical tool depicting latent empirical semi-variograms to detect serial correlation for latent stationary linear mixed models. We apply our proposed model to examine the treatment effect on patients having the amyotrophic lateral sclerosis disease. The result shows that the treatment can slow down progression of latent cervical and lumbar functions.",
keywords = "Als, Ornstein‐, Uhlenbeck, Latent linear mixed model, Serial correlation",
author = "Tran, {Trung Dung} and Emmanuel Lesaffre and Geert Verbeke and Geert Molenberghs",
note = "Funding Information: information KU Leuven, C24/15/034The authors obtained financial support from the grant C24/15/034 of KU Leuven, Belgium. ALS Data used in the preparation of this article were obtained from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database. In 2011, Prize4Life, in collaboration with the Northeast ALS Consortium, and with funding from the ALS Therapy Alliance, formed the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Consortium. The data available in the PRO-ACT Database has been volunteered by PRO-ACT Consortium members. As such, the following organizations and individuals within the PRO-ACT Consortium contributed to the design and implementation of the PRO-ACT Database and/or provided data, but did not participate in the analysis of the data or the writing of this report: Neurological Clinical Research Institute, MGH; Northeast ALS Consortium; Novartis; Prize4Life Israel; Regeneron Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries, Ltd. Funding Information: The authors obtained financial support from the grant C24/15/034 of KU Leuven, Belgium. ALS Data used in the preparation of this article were obtained from the Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) Database. In 2011, Prize4Life, in collaboration with the Northeast ALS Consortium, and with funding from the ALS Therapy Alliance, formed the Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) Consortium. The data available in the PRO‐ACT Database has been volunteered by PRO‐ACT Consortium members. As such, the following organizations and individuals within the PRO‐ACT Consortium contributed to the design and implementation of the PRO‐ACT Database and/or provided data, but did not participate in the analysis of the data or the writing of this report: Neurological Clinical Research Institute, MGH; Northeast ALS Consortium; Novartis; Prize4Life Israel; Regeneron Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries, Ltd. Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons Ltd",
year = "2021",
month = feb,
day = "10",
doi = "10.1002/sim.8790",
language = "English",
volume = "40",
pages = "578--592",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley & Sons Inc.",
number = "3",
}